2017 Annual Meeting Presentations

Annual Meeting

**See the 2017 Photos Here**

Presentations

Presentations are provided in PDF with author's permission. Use the links below to find the session you're looking for. Sessions and presentations will be added as permissions are provided. For presentations that are not provided contact IMPAACT Operations for contact information.

MDR-TB Training

IMPAACT Plenary 1

IMPAACT Plenary 2

Study Coordinators Meeting

Adherence Working Group Meeting

TB Scientific Committee

Cure Scientific Committee

Complications and Co-Morbidities Scientific Committee

Treatment Scientific Committee

Prevention Scentific Committee

ICAB Presentations

MDR-TB Training

Monday, 29 May 2017

Title

Slides

Video Presentation

Speaker(s)

Principles of TB Epidemiology in Children, Including Contact Investigation
View

Watch

Anneke Hesseling

Screening, Diagnosis and Management of MDR-TB in Children
View

Watch

Simon Schaaf

Adverse Effects of Existing Second-line and Novel Antituberculosis Drugs in Children with Multidrug-resistant Tuberculosis
View

Watch


Tony Garcia-Prats

Approach to MDR-TB microbiology in children

View

Anne-Marie Demers

Respiratory Specimen Collection for TB Investigation


Watch

 

CXR reading for IMPAACT
View
Watch

Simon Schaaf

Pediatric ECG evaluation for MDR-TB trials
View
Watch

James Nielsen

A5300/I2003/PHOENIx Preparatory Study of MDR TB Cases and Their Household Contacts: Operational Feasibility to Inform PHOENIx Trial
View

Watch

Amita Gupta and
Vanessa Rouzier

 

IMPAACT Plenary 1

Tuesday, 30 May 2017

Moderators: Sharon Nachman, MD and James McIntyre, MD

Perspectives from the Office of AIDS Research Maureen Goodenow, PhD
State of the Network

Sharon Nachman, MD

Behavioral and Social Science in Biomedical HIV Research

Michael Stirratt, PhD

Adolescent Pregnancy and Retention on Antiretroviral Therapy Elaine Abrams
Challenges to Eliminating HIV Among Adolescents

Mary Jane Rotheram, PhD

Turning the Corner on the AIDS Pandemic: Refining the Science-Driven HIV Research Enterprise


Carl Dieffenbach, PhD

 

IMPAACT Plenary 2

Wednesday, 31 May 2017

Grace Aldrovandi, MD and James McIntyre, MD

Studies Toward Understanding the Role of Integrin a4b7 in HIV and SIV Transmission and Pathogenesis

James Arthos, PhD

Cytotoxic T-cell Responses and HIV Cure

Brad Jones, PhD

Long-acting Methods

Raphael Landovitz, MD, Msc


PROMISE Updates and Key Safety Findings




Mary Glenn Fowler, MD
Lynda Stranix-Chibanda, MD
Amita Gupta, MD, MHS


Statistical Issues in IMPAACT Studies

Terence Fenton, EdD

Grace Montepiedra, PhD
Site Recognition Awards James McIntyre, MD

 

Adherence Working Group Meeting

Tuesday, 30 May 2017

Welcome, year in review and goals

K. Rivet Amico
Sybil Hosek

Adherence Measurement and Support in IMPAACT Studies

PROMISE 1077BF: Breastfeeding Version of the PROMISE Study: Promoting Maternal and Infant Survival Everywhere


Pamela Murnane

IMPAACT 2009: Feasibility, Acceptability and Safety of Oral Pre-Exposure Prophylaxis for Primary HIV Prevention during Pregnancy and Breast Feeding in Adolescents and Young Women


Sybil Hosek

IMPAACT 2017: Phase I/II Study of the Safety, Acceptability, Tolerability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Long-Acting Injectable Rilpivirine in Virologically Suppressed HIV-Infected Children and Adolescents


Liz Lowenthal

A5300B/IMPAACT 2003B – PHOENix MDR TB: Protecting Households on Exposure to Newly Diagnosed Index Multidrug-Resistant TB Patients

Amita Gupta
Anneke Hesseling

IMPAACT 2010/VESTED: Phase III Study of the Virologic Efficacy and Safety of Dolutegravir-Containing versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and their Infants


Shahin Lockman
Lameck Chinula

 

Study Coordinators Meeting

Wednesday, 31 May 2017

Key Updates and Operational Updates


IMPAACT Ops Representatives:
Kat Calabrese
Katie McCarthy

IMPAACT Site Overviews


Sadaf Inamdar
Jorge Pilotto
Vanessa Rouzier

 

Tuberculosis Scientific Committee

Tuesday, 30 May

Welcome and Overview of Tuberculosis Scientific Agenda

Anneke Hesseling

Tuberculosis Prevention and Treatment Study Updates

PHOENIx (A5300/IMPAACT 2003): Study of MDR TB Cases and Their Household Contacts: Operational Feasibility to Inform PHOENIx Trial Design


Amita Gupta

IMPAACT 2001: Trial of the Pharmacokinetics, Tolerability, and Safety of Once-Weekly Rifapentine and Isoniazid in HIV-infected and HIV-1-uninfected Pregnant and Postpartum Women with Latent Tuberculosis Infection


Jyoti Mathad

P1108: A Phase I/II, Open-Label, Single Arm Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Bedaquiline (BDQ) in Combination with Optimized Individualized Multidrug-Resistant Tuberculosis (MDR-TB) Therapy in HIV-Infected and HIV-Uninfected Infants, Children and Adolescents with MDR-TB Disease



Anneke Hesseling

IMPAACT 2005: A Phase I/II Open-label, Single-Arm Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination with Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in HIV-infected and HIV-uninfected Children with MDR-TB



Ethel Weld

The Future of MDR-TB Treatment in Children

SMaRT Kids, the Adult MDR-TB Trials Landscape and Moving Pediatric TB Trials Forward


Tony Garcia-Prats

Emerging Data on Delaminid Pharmacokinetics and Safety in Children with MDR-TB

Jeffrey Hafkin

Using Pharmacokinetic Modelling to Evaluate Novel TB Drugs in Children More Efficiently: Experiences from BDQ CRUSH, P1108 and IMPAACT 2005


Elin Svensson

Update on Phenotypic and NGS-based Advances for Drug Susceptibility Testing and Their Use in Context of Clinical Trials


Marco Schito

Quantification of Circulating Mtb Antigen Peptides for Rapid Diagnosis and Treatment Monitoring


Tony Hu


Novel Blood-based Biomarkers for Pediatric TB

Jeff Tornheim
Mandar Paradkar


     

Cure Scientific Committee

Wednesday, 31 May

Committee Updates
P1115 Study Status Updates
Deborah Persaud
Ellen Chadwick
Biomarkers of HIV persistence as predictors of HIV Rebound off ART Robert Siliciano
Is HIV-1 antibody a useful biomarker for cure studies?

Katherine Luzuriaga

Effect of very early ART and therapeutic vaccines on reservoir size and viral rebound in non-human primates


Afam Okoye

Pediatric experience with ART interruption: what’s to fear?

William Borkowsky

Considerations for ART interruption in African infants participating in P1115

Mutsa Bwakura-Dangarembizi

 

Complications and Co-Morbidities Scientific Committee

Wednesday, 31 May

Neurodevelopment and Mental Health

Neurovirology of HIV Infection: New Directions for Clinical Research

Avi Nath

Update on IMPAACT NWCS 604 (Early Investigator Award)

David Bearden

Update on IMPAACT P1104s/ PROMISE (1077BF)/ Neurodevelopmental sub-study findings

Michael Boivin
Miriam Chernoff

Update on IMPAACT 2002: Combined Cognitive Behavioral Therapy and a Medication Management Algorithm for Treatment of Depression among Youth Living with HIV in the United States


Larry Brown

Update on IMPAACT 2016: Evaluating a Group-Based Intervention to Improve Mental Health and ART Adherence in Adolescents Living with HIV in Low Resource Settings


Geri Donenberg

Metabolic and Infectious Complications

Cardiovascular Complications of HIV Infection? Lessons learned from other inflammatory conditions in children and adolescents


Elaine Urbina

IMPAACT P1072 Secondary Analysis Results

Adriana Weinberg

Updates on RSV Studies: IMPAACT 2011, 2012, 2013

Betsy McFarland
Coleen Cunningham

 

Treatment Scientific Committee

Thursday, 1 June

Welcome and Overview of Treatment Scientific Agenda

Elaine Abrams
Ted Ruel

ART for Pregnant and Breastfeeding Women:
Considerations for Women and Their Babies

Maternal and Infant Health Outcomes in the Context of Universal Antiretroviral Treatment

Jennifer Jao

Pharmacokinetics/Pharmacodynamics and Safety of ARVs During Pregnancy

Brookie Best

Pharmacokinetics/Pharmacodynamics and Safety of ARVs During Breastfeeding

Edmund Capparelli

IMPAACT HIV Treatment Study Updates

IMPAACT 2010/VESTED: Phase III Study of the Virologic Efficacy and Safety of Dolutegravir-Containing versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and their Infants


Lameck Chinula

P1026s: Pharmacokinetic Properties of Antiretroviral Therapy During Pregnancy

Mark Mirochnick

P1093: Phase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of GSK1349572 (Dolutegravir), a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and Adolescents


Ted Ruel

P1101: Phase I/II Dose-Finding, Safety, Tolerance, & PK Study of Raltegravir-Containing ART Regimen in HIV-Infected & TB Co-Infected Children


Tammy Meyers

P1106: Pharmacokinetic Characteristics of Antiretrovirals and Tuberculosis Medicines in Low Birth Weight Infants


Adrie Bekker

P1097: Raltegravir Pharmacokinetics and Safety in Neonates; and P1110: A Phase I Trial to Evaluate the Safety and Pharmacokinetics of Raltegravir in HIV-Exposed Infants at High Risk


Diana Clarke

IMPAACT 2007: Phase I Safety & Pharmacokinetics of Maraviroc in HIV-1-Exposed Neonates at Risk of Acquiring HIV-1 Infection


Ellen Chadwick

IMPAACT 2014: Phase I/II Trial of PK, Safety, & Tolerability of Doravirine & Doravirine/3TC/TDF in HIV-1-Infected Children & Adolescents


Ann Melvin

IMPAACT 2017: Phase I/II Study of Safety & PK of Oral & Long-acting Injectable Cabotegravir & Rilpivirine in Virologically Suppressed HIV-Infected Adolescents


Carolyn Bolton

 

Prevention Scentific Committee

Thursday, 1 June

Prevention of Vertical Transmission of HIV

Modelling HIV Prevention Modalities for Children

Andrea Ciaranello

Primary Prevention in Adolescents and Youth – ARV Strategies

Study update for IMPAACT 2009: Feasibility, Acceptability and Safety of Oral Pre-Exposure Prophylaxis for Primary HIV Prevention during Pregnancy and Breast Feeding in Adolescents and Young Women


Sybil Hosek

Immune Strategies for HIV Prevention

Study update for IMPAACT P1112: Phase I Study to Determine Safety and Pharmacokinetic Parameters of Subcutaneous VRC01, a Potent Anti-HIV Neutralizing Monoclonal Antibody, in HIV-1 Exposed Infants


Coleen Cunningham


The Development of Broadly Neutralizing Antibodies in HIV-Infected Infants


Cassie Simonich
Julie Overbaugh

Pre-Clinical Infant HIV Vaccine Studies in Non-Human Primates

Kristina DeParis

Safety and Immunogenicity of HIV Vaccines in Infants

Giny Fouda


Funded by the National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Institute of Mental Health of the US National Institutes of Health, US Department of Health and Human Services.